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Abstract
Background
Direct-acting antivirals (DAA) have demonstrated high efficacy to achieve sustained virologi-
cal response (SVR) in chronic hepatitis C patients. We aim to assess the change in health-
related quality of life (HRQoL) among patients successfully treated, and to identify predictors
of this variation.
Methods
In a prospective observational study, patients with chronic hepatitis C who started DAA ther-
apy between May 2016 and April 2017 completed the EQ-5D-5L questionnaire at baseline
and 12 weeks after the end of therapy before knowing the virological result. Analysis
included all patients with SVR.
Results
Median baseline EQ-5D-5L scores of the 206 enrolled patients were 0.857 utility and 70.0
visual analogue scale (VAS). Following SVR, a reduction occurred in the proportion of
patients with mobility problems (35% vs 24%, p = 0.012), pain/discomfort (60% vs 42%,
p<0.001) and anxiety/depression (57% vs 44%, p = 0.012), with an increase in utility
(+0.053, p<0.001) and VAS (+10, p<0.001). Score improvements were also observed in cir-
rhotic (+0.048 utility, p = 0.027; +15 VAS, p<0.001) and HIV co-infected patients (+0.039
utility, p = 0.036; +5 VAS, p = 0.002). In multivariate analyses, middle age (45–64 years)
and baseline anxiety/depression were associated to greater improvement in utility after
SVR, and moderate-advanced liver fibrosis and cirrhosis to greater increase in VAS score.
Low baseline values were associated to greater improvements in utility value and VAS
score.
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Conclusions
The cure of chronic hepatitis C infection with DAA has a short term positive impact on
HRQoL with improvement in mobility, pain/discomfort, anxiety/depression, utility value and
VAS score. Patients with poor baseline HRQoL were the most beneficed.
Introduction
Chronic hepatitis C constitutes a well-recognize global public health issue, mainly due to its world-
wide high prevalence and the serious consequences of progression of disease. Hepatitis C virus
(HCV) leads to cirrhosis in up to 20% of those chronically infected [1] and of these, 2–4% annually
develop hepatocellular carcinoma [2]. Moreover, chronic HCV infection is the primary indication
for liver transplantation in developed countries [3]. The economic burden is multiplied by the
impact of HCV on health related quality of life (HRQoL), appreciable at any stage of severity [4,5].
Complications of advanced liver disease such as encephalopathy, variceal hemorrhage, and ascites
have been reported to negatively affect HRQoL [6,7]. Extrahepatic manifestations related to HCV
as fatigue, irritability, depression, muscle pain, joint pain and cognitive impairment may also influ-
ence the patient’s psychological well-being and self-perceived health [8,9].
Measuring HRQoL has become important in clinical research, as it is considered the gold stan-
dard to report the patient´s experiences with illness and treatment [10,11]. Changes in HRQoL
from the patient perspective before and after health care interventions can be monitorized with
instruments like the EQ-5D [12], a standardized questionnaire that provides a simple, generic
measure of health for clinical and economic appraisal [13]. EQ-5D provides health utilities, widely
used in cost-effectiveness and decision analyses where different treatments are compared.
Antiviral therapies can eradicate the HCV resulting in improvements in liver histology,
morbidity, mortality and enhancing HRQoL because of symptoms´ alleviation [14]. A combi-
nation of pegylated interferon (peg-IFN) and ribavirin (RBV) has long been the standard treat-
ment for chronic hepatitis C, with limited efficacy and significant adverse effects [15]. The
impact of peg-IFN on quality of life was studied in patients with and without HIV co-infection,
showing negative patient experiences [16–17]. However, patients who achieved HCV clearance
experienced significant improvements in HRQoL compared to non-responders [17–19].
New direct acting antiviral regimens (DAA) have changed the landscape of treatment of
chronic hepatitis C. DAA provide important advantages, including higher efficacy, shorter
duration of treatment and an optimal safety profile [20–22]. However, there is little data
regarding the effect of the new regimens on HRQoL and most of the evidence comes from
clinical trials, in which certain subpopulations are underrepresented, such as psychiatric
patients, those coinfected with HIV or those with addictive behaviours [23,24]. Assessment of
HRQoL in real life from chronic hepatitis C patients is needed to evaluate the economic and
health impact of these new therapies [25].
The main objective of this study was to assess short-term changes in HRQoL and health
utilities among chronic hepatitis C patients receiving successful treatment with DAA. Second-
ary objectives were to analyse the influence of treatment in domains of EQ-5D-5L question-
naire, and to identify the predictors of change in HRQoL after HCV clearance.
Patients and methods
Design and study population
A prospective observational study was conducted in a regional reference hospital in northern
Spain. Patients with chronic HCV infection who started interferon-free treatments with DAA
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between May 2016 and April 2017 were invited to participate. Exclusion criterion was inability
to understand Spanish.
In accordance with the clinical practice guidelines and the centre’s treatment protocol,
patients started therapy with a variable duration of 8 to 24 weeks. Three interviews were con-
ducted by the same investigator. The first was face-to-face, providing information to the
patient and obtaining the written informed consent. Successive interviews were carried out by
telephone in week 4 of treatment and 12 weeks after its completion (post-12), time when the
sustained virologic response (SVR) is assessed, revealing the cure or not of the HCV infection.
Patients were considered to have achieved SVR if they had undetectable HCV-RNA at post-12
week. The last interview was conducted before the follow-up medical visit, so that the patient
and the interviewer were still unaware of the analytical data and treatment’s outcome.
According to the main objective of the study, only those patients with the three question-
naires completed and who had achieved SVR were included in the analysis.
The study fulfilled all the ethical requirements and was approved by the Clinical Research
Ethics Committee of Navarre.
Assessments
Sociodemographic variables of the patient were recorded at the baseline interview: sex, age,
marital status, educational level and occupational status. Clinical variables were obtained from
the electronic medical record: alcohol consumption and parenteral drug use history, smoking,
body mass index and concomitant diseases, which were assessed using a simplified Charlson
index [26] and the diagnosis count method [27]. In addition, the existence of HIV co-infec-
tion, hypertension, rheumatological disease, paralysis/hemiplegia, depression, anxiety or other
psychiatric illness was specifically collected.
Finally, the variables related to chronic liver disease due to HCV were included: viral geno-
type, previous treatment experience (naïve, pre-treated with IFN or peg-IFN, pre-treated with
DAA), degree of liver fibrosis based on Fibroscan test’s values, categorized according to cut-off
points F0-F1 (<7.5 kPa), F2 (7.5 to 9.4 kPa), F3 (9.5 to 12.4 kPa) and F4 (12.5 kPa), Child-
Pugh score in the cirrhotic patient [28], current combination of DAA, and duration of
treatment.
HRQoL questionnaire
All patients were asked to complete the Spanish version of the EQ-5D, an instrument previ-
ously used to assess HRQoL in patients with chronic hepatitis C [6,29]. Currently, there are
two versions of the EQ-5D of the EuroQol Group, EQ-5D-3L and EQ-5D-5L. In this study the
new version was used, the EQ-5D-5L, that has proven to be valid and more sensitive to
changes in health status [30].
EQ-5D-5L provides a simple description of the patient’s self-perceived health status cover-
ing five health dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/
depression, with five response options (no problems, slight problems, moderate problems,
severe problems and extreme problems). Any response in the items “slight, moderate, severe
or extreme” was considered as having “problems”, for each dimension. The questionnaire also
provides a self-reported Visual Analogue Scale (VAS), which measures the patients’ health on
a scale from 0 to 100, where 0 reflects the worst imaginable health status and 100 the best imag-
inable health status. The patient response in the five dimensions results in a five-digit code,
which can be transformed to a single measure called EQ-5D index or utility value. It ranges
from 0 (reference value assigned to death) to 1 (perfect health), with the possibility of negative
values for health states considered worse than death [31]. It is a health summary score used in
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the clinical and economic evaluation of healthcare as well as in population health surveys [32].
Although the EuroQol Group has already developed a methodology for eliciting value sets for
the 5L version in some countries, no EQ-5D-5L value set was available in Spain at the moment
of the study. Therefore, following the EuroQol recommendation, an interim mapping method
or crosswalk to obtain 5L value sets from the existing 3L values for Spain was used in this study
(available at https://euroqol.org/eq-5d-instruments/eq-5d-5l-about/valuation-standard-value-
sets/crosswalk-index-value-calculator/).
Statistical analysis
Frequencies and proportions were calculated for the categorical variables, and the mean and
standard deviation for continuous variables. For each interview, the proportion of patients with
problems in each of the EQ-5D-5L questionnaire dimension was calculated, and the median of
the utility and the VAS score was estimated. The differences in the medians of these indices were
compared using the Wilcoxon signed rank test. The comparison was repeated in strata by age
group, degree of liver fibrosis, HIV co-infection, simplified Charlson index, duration of treat-
ment, RBV use, considering baseline utility and baseline VAS score above or below the median.
Multivariable linear regression analyses were carried out to identify factors associated with
change in HRQoL, with their β coefficients and 95% confidence intervals (CIs). The differences
between post-12 and baseline scores in utility value and in VAS score were respectively the out-
come variables. A positive β coefficient indicated improvement and a negative coefficient decline
in utility or VAS score after SVR. The adjusted models included sex, age groups (<45; 45–64
and65 years), HIV co-infection, baseline limitation of mobility, baseline anxiety-depression
disorders and degree of liver fibrosis (F0-F1, F2-F3 and F4) before hepatitis C treatment.
Results
Characteristics of patients
A total of 271 patients started treatment during the study period, 214 of those signing the
informed consent (79%). Eight patients were excluded from the final analysis, 4 due to loss
during the follow-up and another 4 due to not achieving SVR, leaving 206 patients cured of
chronic HCV infection. The average age was 52.3 years (SD = 9.0) and 66% were males. HIV
co-infected patients represented 32% of the population. The simplified Charlson score was2
in 22 patients (11%) and 90% had at least one comorbidity, the most frequent being a psychiat-
ric disorder (34%), hypertension (23%) and rheumatological diseases (12%). A total of 66%
patients were smokers, 16% had a history of alcohol abuse and 52% had a history of parenteral
drug use as probable mode of HCV transmission (Table 1).
The most frequent HCV genotypes were 1a (39%), 1b (24%) and 3 (21%). Liver fibrosis
degree was F0-F1 in 51 (25%) patients, F2-F3 in 97 (47%) and F4 in 58 (28%) patients. Among
95% of cirrhotic patients had compensated liver disease (Child-Pugh A).
DAA combinations used were ombitasvir/paritaprevir/ritonavir +/- dasabuvir (39%), sofos-
buvir/ledipasvir (33%), sofosbuvir + daclatasvir (22%), grazoprevir/elbasvir (3%), sofosbuvir/
velpatasvir (1.5%), sofosbuvir (1.5%) and sofosbuvir + grazoprevir/elbasvir (0.5%). The thera-
peutic regimen included RBV in 52% of the cases, and 72% of the treatments lasted 12 weeks. A
majority of the patients (79%) had never received previous treatment for hepatitis C (Table 1).
EQ-5D-5L health dimensions
Prior to the start of treatment, the dimensions in which the patients showed a greater inci-
dence of problems were pain/discomfort (60%), anxiety/depression (57%) and mobility (35%).
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The treatment started having a positive impact on these dimensions from week 4, and on all
liver fibrosis subgroups (Fig 1). The baseline and post-12 comparison of the EQ-5D-5L
Table 1. Socidemographic and clinical characteristics of the patients.
Characteristics Total (n = 206)
Age in years, mean (SD) 52.3 (9.0)
Male sex, n (%) 135 (66)
Marital status, n (%)
Single 70 (34)
Married/Partnered 90 (44)
Divorced 36 (18)
Widow/Widower 10 (5)
Educational level, n (%)
No education 11 (5)
Primary 83 (40)
Secondary 91 (44)
University 20 (10)
Not reported 1 (0.5)
Occupational status, n (%)
Employed 101 (49)
Unemployed 63 (31)
Disabled 29 (14)
Retired 13 (6)
History of parenteral drug use, n (%) 107 (52)
HIV co-infection, n (%) 65 (32)
Comorbidity: Charlson index, n (%)
0–1 184 (89)
2 14 (7)
 3 8 (4)
Total number illnesses, mean (SD) 2.1 (1.4)
Body mass index, mean (SD) a 25.8 (4.9)
HCV Genotype, n (%)
1a 81 (39)
1b 49 (24)
2 7 (3)
3 43 (21)
4 24 (12)
Other 2 (1)
Prior HCV treatment experience, n (%)
Naïve 163 (79)
Interferon failure 41 (20)
Direct acting antiviral failure 2 (1)
Duration of HCV treatment, n (%)
8 weeks 20 (10)
12 weeks 148 (72)
> 12 weeks 38 (18)
Abbreviations: SD, standard deviation; HIV, human immunodeficiency virus; HCV, hepatitis C virus; RNA,
ribonucleic acid; IQR, interquartile range.
aBody mass index is in Kg/m2.
https://doi.org/10.1371/journal.pone.0205277.t001
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questionnaire’s dimensions showed a decrease in the proportion of patients with mobility
problems (35% vs 24%, p = 0.012), pain/discomfort (60% vs 42%, p<0.001) and anxiety/
depression (57% vs 44%, p = 0.012). A statistically non-significant deterioration was observed
in the dimensions of self-care and daily activities (Fig 1, panel A). Patients F0-F1 did not expe-
rience changes statistically significant after treatment (panel B), but improvement on pain/dis-
comfort happened in F2-F3 (p = 0.002; panel C). Cirrhotic patients reported more problems
for all dimensions before treatment, but improvements after therapy occurred in pain/discom-
fort (72% vs 52%, p = 0.036) and in the anxiety/depression dimension (62% vs 45%, p = 0.063),
although the latter did not reach statistical significance (panel D).
Utilities (EQ-5D-5L Index) and VAS score
The median utility was not affected during treatment (0.857, p = 0.324), while the VAS score
showed a 5-point increase, from 70 baseline points to 75 in week 4 (p = 0.049). Poor baseline
scores were associated to significant increases (Table 2).
Fig 1. Percentage of patients reporting problem in any EQ-5D dimension by liver fibrosis stage and study visit. P
values are the comparison of the proportions from baseline and week 12 post-treatment and were calculated by Chi-
square test. (A) Total of study population; (B) F0-F1 patients; (C) F2-F3 patients; (D) Cirrhotic patients.
https://doi.org/10.1371/journal.pone.0205277.g001
Table 2. Changes in health-related quality of life scores from the baseline to the week 4 of treatment with direct-acting antiviral agents.
Utility value Visual analogical scale score
Baseline Week 4 Difference p valuea Baseline Week 4 Difference p valuea
Total (n = 206) 0.857 0.857 0.000 0.324 70.0 75.0 5.0 0.049
Age, in years
< 45 (n = 24) 0.884 0.856 -0.028 0.322 75.0 75.0 0.0 0.792
45–64 (n = 165) 0.857 0.857 0.000 0.404 70.0 70.0 0.0 0.038
 65 (n = 17) 0.857 0.857 0.000 0.044 75.0 80.0 5.0 0.529
Liver fibrosis
F0-F1 (n = 51) 0.893 0.871 -0.022 0.704 75.0 75.0 0.0 0.420
F2-F3 (n = 97) 0.857 0.871 0.014 0.324 70.0 75.0 5.0 0.053
F4 (n = 58) 0.809 0.822 0.013 0.325 60.0 67.5 7.5 0.041
HIV co-infection
Yes (n = 65) 0.871 0.887 0.016 0.797 75.0 70.0 -5.0 0.706
No (n = 141) 0.857 0.857 0.000 0.329 70.0 75.0 5.0 0.039
Comorbidity
Charlson 0–1 (n = 184) 0.857 0.857 0.000 0.399 70.0 75.0 5.0 0.084
Charlson2 (n = 22) 0.784 0.838 0.054 0.702 50.0 60.0 10.0 0.304
Current Rivabirin use
Yes (n = 106) 0.850 0.840 -0.010 0.276 70.0 70.0 0.0 0.373
No (n = 100) 0.857 0.887 0.030 0.019 70.0 77.5 7.5 0.057
Baseline utility
median (n = 108) 0.914 0.910 -0.004 0.001 80.0 80.0 0.0 0.540
< median (n = 98) 0.696 0.783 0.087 0.001 50.0 60.0 10.0 0.005
Baseline VAS score
median (n = 123) 0.910 0.910 0.000 0.141 80.0 80.0 0.0 0.018
< median (n = 83) 0.719 0.799 0.080 0.004 50.0 60.0 10.0 <0.001
Abbreviations: HIV, human immunodeficiency virus; HCV, hepatitis C virus; VAS, visual analogical scale.
aP value obtained by Wilcoxon’s test for repeated measures.
https://doi.org/10.1371/journal.pone.0205277.t002
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In comparison with the baseline value, the utility in post-12 week increased by 6% (+0.053,
p<0.001), and the VAS increased 10 points (+14%, p<0.001). These improvements were sta-
tistically significant in cirrhotic patients (+0.048 utility, p = 0.027, +15 VAS points, p<0.001)
and F2-F3 fibrosis subgroup (+0.053 utility, p = 0.002, +10 VAS points, p<0.001), but not in
those F0-F1 (+0.039 utility, p = 0.061; +5 VAS points, p = 0.148). Analyses stratified by HIV
co-infection, Charlson index and baseline scores showed important increases in the post-12
week utility or VAS score (Table 3).
Multivariable linear regression showed that age between 45–64 years (β = 0.07; 95%CI, 0.01
to 0.13) and suffering anxious or depressive disorders before starting treatment (β = 0.08; 95%
CI, 0.03 to 0.12) were predictive factors of utility improvement after SVR and moderate-
advanced liver fibrosis (β = 5.93; 95%CI, -0.01 to 11.86) and cirrhosis (β = 7.15; 95%CI, 0.64 to
13.65) favourable for increases in VAS score (Table 4).
Poor baseline values of the utility and VAS score, when baseline values were introduced in
their respective models, were the more predictive factors of improvement in the post-12 week
Table 3. Changes in health-related quality of life scores from the baseline to the week 12 post-treatment with direct-acting antiviral agents.
Utility value Visual analogical scale score
Baseline Post-12 Difference p valuea Baseline Post-12 Difference p valuea
Total (n = 206) 0.857 0.910 0.053 <0.001 70.0 80.0 10.0 <0.001
Age, in years
< 45 (n = 24) 0.884 0.892 0.008 0.962 75.0 80.0 5.0 0.100
45–64 (n = 165) 0.857 0.910 0.053 <0.001 70.0 80.0 10.0 <0.001
 65 (n = 17) 0.857 0.857 0.000 0.286 75.0 80.0 5.0 0.139
Liver fibrosis
F0-F1 (n = 51) 0.893 0.932 0.039 0.061 75.0 80.0 5.0 0.148
F2-F3 (n = 97) 0.857 0.910 0.053 0.002 70.0 80.0 10.0 <0.001
F4 (n = 58) 0.809 0.857 0.048 0.027 60.0 75.0 15.0 <0.001
HIV co-infection
Yes (n = 65) 0.871 0.910 0.039 0.036 75.0 80.0 5.0 0.002
No (n = 141) 0.857 0.893 0.036 <0.001 70.0 80.0 10.0 <0.001
Comorbidity
Charlson 0–1 (n = 184) 0.857 0.910 0.053 <0.001 70.0 80.0 10.0 <0.001
Charlson2 (n = 22) 0.784 0.857 0.073 0.316 50.0 70.0 20.0 0.004
Current HCV treatment duration
8 weeks (n = 20) 0.857 0.850 -0.007 0.532 75.0 80.0 5.0 0.312
12 weeks (n = 148) 0.857 0.910 0.053 <0.001 70.0 80.0 10.0 <0.001
> 12 weeks (n = 38) 0.840 0.878 0.038 0.052 60.0 80.0 20.0 <0.001
Current Rivabirin use
Yes (n = 106) 0.850 0.910 0.060 <0.001 70.0 80.0 10.0 <0.001
No (n = 100) 0.857 0.902 0.045 0.014 70.0 80.0 10.0 0.001
Baseline utility
median (n = 108) 0.914 1.000 0.086 0.688 80.0 85.0 5.0 0.001
< median (n = 98) 0.696 0.820 0.124 <0.001 50.0 70.0 20.0 <0.001
Baseline VAS score
median (n = 123) 0.910 0.932 0.022 0.051 80.0 85.0 5.0 0.061
< median (n = 83) 0.719 0.843 0.124 <0.001 50.0 70.0 20.0 <0.001
Abbreviations: HIV, human immunodeficiency virus; HCV, hepatitis C virus; VAS, visual analogical scale.
aP value obtained by Wilcoxon’s test for repeated measures.
https://doi.org/10.1371/journal.pone.0205277.t003
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in patients with SVR (β = -0.297; 95%CI, -0.403 to -0.190 and β = -0.459; 95%CI, -0.572 to
-0.347, respectively).
Discussion
Successful treatment with DAA on health-related quality of life in patients with chronic hepati-
tis C was associated to significant improvement in the majority of HRQoL domains measured
by the EQ-5D-5L instrument. Improvement of HRQoL started shortly after the initiation of
therapy and enhanced after achieving SVR, including cirrhotic and HIV co-infected patients,
classically considered “difficult to treat” populations. Main improvements occurred in mobil-
ity, pain/discomfort and anxiety/depression dimensions, as well as in the health utility and
VAS score. Although evidence from “real life” setting is lacking [23], patient reporting out-
comes with DAA in clinical trials also suggest benefit after treatment [33–36]. Relationship
between SVR and HRQoL improvement has not been elucidated, but viral clearance has been
suggested to result in cytokines and inflammatory biomarkers reduction in periphery and cen-
tral nervous system, leading to a positively impact on patients’ experience [37, 38]. The
improvement observed in the well-being of patients cured with DAA reinforces the idea that
chronic HCV infection, far from being a purely hepatic disease, presents a clearly systemic
component and impaires HRQoL [39,40]. According the Spanish National Health Survey
2011/12 [41], the general population aged 45–54 years referred a VAS score of 77.2 and utility
value of 0.928, being higher figures than those referred by our patients before treatment, 70.0
and 0.875, respectively. Lower scores in our patients suggest a HRQoL impairment associated
to chronic hepatitis C infection [7, 29].
In the first 4 weeks of treatment, the median VAS score increased 5 points and improved
health dimensions that were negatively affected with interferon treatments [42]. This early
improvement in HRQoL has been described for DAA [35], contrary to what happened with
peg-IFN + RBV and triple therapy with boceprevir or telaprevir [10,17,43,44], which seems to
relate HRQoL deterioration during treatment to interferon and not to second generation
DAA. The use of RBV was not associated with significant disutility, a fact that suggests a lower
impact of side effects such as anaemia and pruritus, when administered in combination with
Table 4. Effect of socio-demographic and clinical factors on post-12 health related quality of life improvement for sustained virological responders.
Baseline characteristics Utility valuea Visual analogical scale scoreb
β coefficient (CI 95%) P value β coefficient (CI 95%) P value
Intercept -0.06 (-0.16 to 0.04) 0.248 -1.26 (-12.45 to 9.92) 0.824
Female sex 0.01 (-0.04 to 0.05) 0.802 2.06 (-3.07 to 7.20) 0.429
Aged 45–64 years vs <45yrs 0.07 (0.01 to 0.13) 0.041 1.81 (-5.34 to 8.96) 0.619
Aged65 years vs <45yrs 0.07 (-0.02 to 0.17) 0.139 -1.46 (-12.15 to 9.22) 0.788
HIV co-infection -0.02 (-0.06 to 0.03) 0.482 -2.92 (-8.08 to 2.24) 0.266
Limitation of mobilityc -0.04 (-0.10 to 0.02) 0.193 -4.70 (-11.18 to 1.77) 0.153
Anxiety/Depression 0.08 (0.03 to 0.12) 0.001 4.37 (-0.75 to 9.48) 0.094
F2-F3 vs F0-F1 liver fibrosis 0.03 (-0.02 to 0.08) 0.297 5.93 (-0.01 to 11.86) 0.050
F4 vs F0-F1 liver fibrosis 0.02 (-0.04 to 0.08) 0.422 7.15 (0.64 to 13.65) 0.031
Linear regression adjusted by sex, age groups, HIV co-infection, limitation of mobility, anxious-depression disorders and liver fibrosis.
Abbreviations: HIV, human immunodeficiency virus.
aDependent variable is the difference post-12 minus baseline utility value.
bDependent variable is the difference post-12 minus baseline visual analogical scale score.
cLimitation of mobility was defined by rheumatic disease, morbid obesity or paralysis/hemiplegia.
https://doi.org/10.1371/journal.pone.0205277.t004
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DAA compared to when administered with interferon. This aspect reinforces the idea of the
good tolerability of DAA in real life conditions [45,46].
In clinical practice, patient reporting outcomes constitute useful tools in the evaluation and
monitoring of health interventions, since they provide information on patient perception and
needs [47]. Knowing the predictors of HRQoL improvement after the treatment of hepatitis C
can help to strengthen patient adherence and motivation. Middle age, baseline anxiety-depres-
sion, advanced fibrosis and cirrhosis were found to be the most consistent predictors of
HRQoL improvements after SVR. Precisely, those factors have been previously associated with
impairment in HRQoL among chronic hepatitis C patients [4,29,48] and appear to be key
determinants for HRQoL deterioration prior to therapy [14]. The high prevalence of depres-
sion and anxiety in HCV patients before treatment initiation [49] would reinforce the need for
psychosocial screening, even more when considering that a greater HRQoL improvement may
occurs in those patients after SVR. In our study, patients with worse baseline HRQoL score
showed more significant improvements, a common finding in all types of clinical trials [50].
This result is consistent with the greater improvement in HRQoL in cirrhotic patients, with
comorbidity or HIV co-infection, observed in the stratified analysis of the study.
This study provides useful information for cost-effectiveness analysis. Utility values allow to
obtain quality adjusted life years, and to estimate incremental cost-utility ratios in pharmacoe-
conomic analysis. Since the advent of second-generation DAA, some cost-utility analyses have
been published to assess their efficiency [51–54], with more or less favourable incremental cost-
utility ratios depending on the degrees of liver fibrosis, the cost of the drugs and the previous
treatment experience. More favourable treatment efficiency in patients with a high degree of
fibrosis is derived from the potential more imminent progression to severe stages, associated
with greater disutility and greater consumption of health resources [51,52]. According to our
results, the more significant HRQoL improvement in cirrhotic patients after the SVR reinforces
this idea. In any case, a decline in the cost of drugs and the possibility of currently treating
patients with a low degree of liver fibrosis with short 8-week regimens, would reduce the incre-
mental cost-utility ratios and improve the efficiency of treatment in all patient subpopulations.
This real-life prospective study included hepatitis C patients who received treatment in a
regional reference hospital in northern Spain. Although the epidemiology of HCV infection
and the introduction of DAA have been relatively homogeneous in Spain, we can not rule out
some geographical differences which would affect representativeness of our study. However,
patients were infected by all HCV genotypes with a distribution similar to that of the popula-
tion in our environment [55], in the different stages of the disease, treated with all available
combinations of DAA and without excluding patients with comorbidity. The indication and
choice of treatment was based on the same protocol, developed according to clinical and effi-
ciency criteria. HRQoL was analysed including subpopulations of patients usually underrepre-
sented in clinical trials, such as those with psychiatric disorders or persons co-infected with
HIV [23], which represent one third of the population in this study. All the interviews were
carried out by the same investigator, in order to minimize the potential bias of the interviewer.
The timing of the interview may affect the results. The post-12 interview was conducted in our
study before knowing the SVR result, in order to avoid the possible overestimation on patient’s
HRQoL self-assessment secondary to the euphoria experienced at that moment [43,56]. How-
ever, when patients know HCV become negative after treatment, the worry about the compli-
cations of the disease probably decrease and an improvement in the anxiety dimension could
be greater than that observed in our study. A long-term evaluation of HRQoL after SVR would
contribute to understand the effect of timing on HRQoL results.
Two possible shortcomings of our study need to be considered. First, the population size,
although similar or greater than that of other observational studies [35,14,57] was not large
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enough to obtain conclusive results in some subanalyses. In any case, the patients included
accounted for 78% of the patients who received treatment successfully during the study period.
Second, the EQ-5D-5L is a generic questionnaire. Although it has been used in many scenar-
ios, including chronic hepatitis C and its treatment, its combination with a disease-specific
questionnaire would have been desirable. Time-related limitations in terms of patient care in
the consulting room and of personnel related to completing the interviews discouraged the use
of other questionnaires. However, studies that use both types of tools for measurement of
patient reporting outcomes in patients treated with DAA therapy obtained similar results and
good correlation between the generic and HCV-specific questionnaires [10,35]. EQ-5D-5L
version was used in this study, as it has demonstrated to be a valid extension of EQ-5D-3L,
providing more precise measurement at both individual and group level [58–61]. Since no 5L
value sets were yet available in Spain, the crosswalk value set was used in this study, as the
EuroQol recommended [31].
The new antivirals available recently seem to improve even more the treatment outcomes,
being expected this same effect on quality of life.
Conclusions
In summary, this study shows a short-term positive impact of SVR on the HRQoL of patients
with chronic hepatitis C treated with interferon-free DAA. The greatest impact was on health
dimensions of mobility, pain/discomfort, anxiety/depression, and in utility values and the
VAS of the EQ-5D-5L questionnaire. The treatment did not produce disutility, nor did the use
of RBV. Predictors of greater improvements in HRQoL with SVR may be baseline depression,
anxiety, moderate-advanced fibrosis and cirrhosis; which may help to give priority to patients
for treatment. The results obtained provide the patient’s perspective in the assessment of DAA
and information on patient reporting outcomes to be incorporated in cost-utility studies.
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